Silence Therapeutics (SLNCF) Return on Equity (2021 - 2025)
Historic Return on Equity for Silence Therapeutics (SLNCF) over the last 5 years, with Q3 2025 value amounting to 0.77%.
- Silence Therapeutics' Return on Equity fell 1400.0% to 0.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77%, marking a year-over-year decrease of 1400.0%. This contributed to the annual value of 0.58% for FY2024, which is 16000.0% up from last year.
- As of Q3 2025, Silence Therapeutics' Return on Equity stood at 0.77%, which was down 1400.0% from 0.8% recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Return on Equity registered a high of 0.39% during Q2 2024, and its lowest value of 7.4% during Q1 2022.
- For the 5-year period, Silence Therapeutics' Return on Equity averaged around 2.1%, with its median value being 1.58% (2021).
- Per our database at Business Quant, Silence Therapeutics' Return on Equity surged by 47600bps in 2023 and then tumbled by -4100bps in 2025.
- Over the past 5 years, Silence Therapeutics' Return on Equity (Quarter) stood at 3.71% in 2021, then tumbled by -100bps to 7.4% in 2022, then surged by 64bps to 2.69% in 2023, then skyrocketed by 85bps to 0.41% in 2024, then plummeted by -88bps to 0.77% in 2025.
- Its last three reported values are 0.77% in Q3 2025, 0.8% for Q2 2025, and 0.63% during Q1 2025.